anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Monocyte-derived alveolar macrophages drive lung injury and fibrosis in murine models and are associated with pulmonary fibrosis in humans. Monocyte-derived alveolar macrophages have been suggested to develop a phenotype that promotes lung repair as injury resolves. We compared single-cell and cytokine profiling of the alveolar space in a cohort of 35 patients with post-acute sequelae of COVID-19 who had persistent respiratory symptoms and abnormalities on a computed tomography scan of the chest that subsequently improved or progressed. The abundance of monocyte-derived alveolar macrophages, their gene expression programs, and the level of the monocyte chemokine CCL2 in bronchoalveolar lavage fluid positively associated with the severity of radiographic fibrosis. Monocyte-derived alveolar macrophages from patients with resolving or progressive fibrosis expressed the same set of profibrotic genes. Our findings argue against a distinct reparative phenotype in monocyte-derived alveolar macrophages, highlighting their utility as a biomarker of failed lung repair and a potential target for therapy.
To improve and promote wound healing and cell regeneration, topical insulin preparations are produced and contain insulin which is in concentrations which are pharmacologically effective for local applications and which is in preparations pharmaceutically suitable for topical applications, preferably emulsion or suspension, cream, ointment, gel or a plaster system. To increase the efficacy of the topical forms they can contain as additional ingredients substrates such as simple sugars, cofactors such as electrolytes, peptides other than insulin, protease inhibitors and antioxidants to prevent inactivation and degradation. The lipid phases used in emulsions are preferably physicochemically and toxicologically suitable mixtures of partial glycerides of chain length C6-C18. It is possible to use vehicles with particular adhesiveness for wounds for internal topical applications. The topical insulin preparations are physiologically adjusted, pharmaceutically specified topical systems for wound healing and cell regeneration with biochemically intensified local activity. They extend the current possibilities for the therapy of wound healings and cell regenerations which are slowed down metabolically, physically or due to perfusion.
Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity and recent estimates showed increase in its prevalence over the last decade to \> 185 million infections worldwide. Prevalence HCV infection in Egypt is the highest in the world.Chronic viral hepatitis infection increases liver fibrosis and stiffness and is an important cause of liver cirrhosis. Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related death in Egypt.It could be considered a special type of metabolic diseases involving insulin resistance (IR) which accelerates fibrosis and modulation of lipid-cholesterol biosynthesis with increased risk for ischemic heart diseases .Increased prevalence of IR and type 2 diabetes mellitus extensively reported in HCV infections.Interferon (INF) based therapy was used in chronic HCV patient and investigators reported that it's effective in eradicating HCV RNA and improving liver fibrosis. However, It's associated with several side effects.Novel direct antiviral agents (DAA) for chronic hepatitis C have entered clinical practice. This therapeutics has minimal side effects and achieves sustained virological response (SVR) rates of above 90% of patients and they are shorter and simpler regimens.Liver fibrosis severity assessment is important when staging chronic HCV and it reflects impact of serological viral eradication on hepatic damage and fibrosis. Although liver biopsy is the gold standard procedure for fibrosis assessment, but non-invasive new approaches have been strongly recommended for evaluation of fibrosis, mainly in HCV. They have no complications and have good diagnostic accuracy. One of the most used non-invasive mechanical methods based on ultrasound is transient elastography (Fibro Scan). Although association of baseline metabolic characteristics with treatment outcome has not been fully assessed for DAAs, this group was reported to result in improved rates of SVR and to reduce the predictive ability of these factors except for the baseline low density lipoprotein. The highest prevalence of HCV was reported in Egypt, where genotype 4 is responsible for 91% of infections and DAAs represented main line of treatment in most centers.Although the changes in lipid metabolism after treatment with DAAs were reported for other genotypes. It was not fully studied in genotype 4 infected patients.
The present invention relates to a method of treating a chronic pelvic inflammatory disease by the cooperative two unite treatment of the specific electromagnetic wave thermal therapy and the traditional Chinese medicines. Before the treatment, a patient is enjoined to relieve the bowels and wipe the residual urine, then a bag of 50 ml traditional Chinese medicine enema soup is used, and the temperature of the liquid medicine is between 38 DEG C and 40 DEG C. The patient lies at a lateral position(namely, the buttock is cushioned slightly) and retention enema is carried out by coating the paraffin oil on a one-off anal tube for lubrication, and the medicine liquid which is made from the traditional Chinese medicines, such as the golden cypress, the seed of cowherb, the rhizoma smilacis glabrae, the peach kernel, the red flower, etc., is retained in the enteric cavity more than 2 hours. Then wet compress is carried out on the hypogastric region with gynecologic inflammation treatment powder, and the wet compress area is about 5*10 square centimeters. On the basis, the patient is treated by a specific electromagnetic wave therapeutic apparatus, is treated 40 minutes each time and is treated once a day. Five days are a course of treatment, the patient needs 2-3 continuous courses of treatment, and suspends the treatment at menstrual period. The medicines of the present invention are composed of the traditional Chinese medicines, such as the golden cypress, the seed of cowherb, the rhizoma smilacis glabrae, the peach kernel, the red flower, etc., are rich in various active constituents, and possess the pharmacological activities, such as anti-inflammatory, blood circulation invigoration, etc.
Risk Summary

There are no data available on the presence of lubiprostone in human milk or the effect of lubiprostone on milk production. There are limited data available on the effect of lubiprostone on the breastfed infant. Neither lubiprostone nor its active metabolite (M3) were present in the milk of lactating rats. When a drug is not present in animal milk, it is likely that the drug will not be present in human milk. If present, lubiprostone may cause diarrhea in the breastfed infant (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for lubiprostone and any potential adverse effects on the breastfed infant from lubiprostone or from the underlying maternal condition.

Clinical Considerations

Infants of nursing mothers being treated with lubiprostone should be monitored for diarrhea.
The invention relates to application of diterpenoid DB-022133 in preparation of a medicine for treating gastric cancer, and belongs to the field of biological medicines. Application of diterpenoid DB-022133 in preparing medicine for treating gastric cancer is provided. It can obviously inhibit the proliferation of gastric cancer cells and obviously promote the death of gastric cancer cells. It can obviously inhibit the migration and invasion of gastric cancer cells. It can obviously destroy the form of gastric cancer cells, resulting in swelling and death of the cancer cells. The medicine for treating gastric cancer comprises effective dose of diterpenoid DB-022133 and pharmaceutically acceptable carrier. The dosage form is one of powder, fine granule, capsule or tablet. The invention has the following advantages: DB-02213 can obviously inhibit the proliferation of gastric cancer cells, obviously destroy gastric cancer cytoskeletons and promote the apoptosis of the gastric cancer cells; provides a new compound medicine for the treatment of gastric cancer; provides a new application direction for the compound.
ALVAC-HIV vCP205 is a second-generation candidate vaccine that can be used to induce a humoral and cellular response against several antigens. vCP205 expresses proteins from two strains of HIV (MN and LAI). rgp120/HIV-1SF2 expresses proteins from a different strain of HIV. This study will help to show how the immune system responds to proteins from more than one strain of virus.

Six groups of 25 volunteers each are randomized to receive simultaneous or sequential doses of ALVAC-HIV vCP205 and SF2 rgp120 or control vaccines (ALVAC-RG rabies glycoprotein vCP65 or BIOCINE Placebo Vaccine 2). In each group, 21 volunteers receive vaccine and 4 receive control vaccines. Volunteers are stratified by lower or higher risk sexual behavior. Immunizations are given to three groups at months 0, 1, 3, 6, 9, and 12, and to the other three groups at months 0, 1, 6, 9, and 12. Volunteers are followed for 24 months.
Need to Know is based on a framework of positive youth development intended to delay sexual initiation and reduce the rate of teenage pregnancy. The N2K curriculum is designed to support the treatment participants throughout their high school career with consecutive dosage for three years from 9th through 11th grade. The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.

The 9th grade course is N2K: Basics and consists of lessons that encourage self-discovery and goal setting, discuss human growth and development, adolescent risk behaviors, communication, STDs, abstinence, contraceptives, teen dating violence, legal issues, responsible media use, refusal skills, and role-playing. The 10th grade N2K: Decisions consists of lessons that increase decision making skills, clarify values, promote healthy relationships and the benefits of delaying sex, and review of anatomy, contraceptives, STDs, and legal issues. It promotes the development of critical thinking skills and application of the facts to real life situations. N2K: Decisions includes an original webisode series of 11 episodes, the first of which is viewed in class, and the others can be viewed online outside of class. The webisode series adds narrative to the basic facts being presented in class. The series runs, in conjunction with the 10th grade curriculum lessons 3-8. The 11th grade N2K: Relationships reinforces basic themes taught in prior years. It emphasizes healthy relationships, healthy living, and taking responsibility for personal health as an adolescent matures into adult life. The last three lessons are a culminating activity that allows participants to express what they have learned and present it to others. About 35% of the 48 sessions focuses on abstinence, 27% highlight positive youth development (PYD), 13% discuss risky behaviors, 12% address STDs, 8% cover contraceptives, and 5% discuss anatomy and puberty in the cumulative three years of the N2K Curriculum.

A paper and pencil survey was administered in school to assess program impacts. Treatment and comparison students were surveyed at baseline (fall 2011 for comparison and fall 2012 for treatment), and for the treatment group, surveying took place before the intervention began. Surveys were administered at the end of each year of programming (end of 9th grade, end of 10th grade, and end of 11th grade), which for the treatment students was after the N2K programming was completed for the year.
A computer-implemented method of operating a diabetes treatment system that includes an insulin pump and a pump controlling device is disclosed. The method includes receiving, by the device, a request for the pump to perform an operation that is dependent on a specified state of the pump. The method also includes requesting, by the device, a current state of the pump from the pump. Moreover, the method includes receiving, by the device, the current state of the pump. Also, the method includes determining, by the device, whether the current state of the pump matches to the specified state of the pump. Additionally, the method includes sending, by the device to the pump, a command to perform the operation in response to a determination that the current state of the pump matches the specified state of the pump.
PURPOSE: To inactivate a filterable pathogen, especially a thermostable virus in a blood plasma preparation by adjusting the water-content of the preparation to a specific level, putting the preparation in a closed vessel, introducing a specific organic compound in gaseous state and heat-treating the preparation. CONSTITUTION: A blood plasma preparation is adjusted to a water-content of 8-40wt.% (preferably by moistening with steam) and put into a closed inactivation vessel. An organic compound selected from ethanol, ethyl acetate, diethyl ether, dimethylformamide, toluene, chloroform, n-heptane, 1,2diacetoxyethane and acetone is introduced into the gaseous phase in the vessel at a concentration of 0.01-10g per 1. liter of the vessel capacity and the content of the vessel is heat-treated wt 50-80 deg.C to inactivate viruses. The heat treatment is preferably carried out in the presence of calcium ion. The calcium ion can be mixed into the preparation at an arbitrary stage in the fractionation of the plasma preparation before freeze-drying. The stability of the plasma preparation activity can be improved by the addition of calcium ion.
The invention relates to medicinal solutions containing super-oxygenated water having a concentration of dissolved oxygen greater than 9.5 milligrams per litre and methods of their use in medical treatment and disinfection. Super-oxygenated water serves to deliver increased concentrations of oxygen intravenously, topically, or through ingestion to the bloodstream, body cells and tissue surfaces to which it is exposed. Bacteria exposed to super-oxygenated water are killed through the oxidation of the polysaccharide cell walls of the bacterial organism. Such solutions act as a disinfectant or preservative during transport of human transplant organs and tissue. The aqueous super-oxygenated solution can be frozen and used as packing ice to simultaneously: cool tissues; disinfect tissues; and provide oxygen through osmosis thereby inhibiting bacterial growth and slowing tissue deterioration. Topical application of super-oxygenated water solutions can increase the delivery of oxygen to exposed surfaces through osmosis. Topical application is useful for immersing or wrapping burned or wounded tissues or the entire body, and promoting faster healing of soft tissues, abrasions, sprains and burns. Topical application in mouth areas can disinfect and increase oxygen delivery in the treatment of gum disease, oral infections and dental infections. Ingestion of super-oxygenated solutions increases the delivery of oxygen to the blood and cells of the body increasing the blood oxygen content and elevating the partial pressure of oxygen in the blood. Intravenous injection of super-oxygenated water as a component of saline or Ringers solutions likewise increases the blood oxygen content and elevates the partial pressure of oxygen in the blood as well as enhancing the uptake of electrolytes, salts and minerals. Targeting specific areas of the body for application of super-oxygenated water is used in the treatment of anaerobic tumours and, heart attacks and brain disorders. Cells of anaerobic tumours are killed or have their rapid growth impeded through exposure to elevated oxygen concentrations. Brain disorder and heart attack effected tissues benefit from elevated oxygen concentrations on targeted exposure to super-oxygenated water solutions.
The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising camphor as an active ingredient. The composition of the present invention, comprising camphor as an active ingredient, inhibits adipocyte differentiation, decreases body fat and abdominal fat, and lowers total cholesterol levels and triglyceride in plasma and triglyceride in the liver, and thus exhibits an activity of preventing or treating obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention significantly decreases fasting blood sugar and blood insulin levels, to thereby improve insulin resistance and metabolic diseases closely involved in insulin resistance. Further, the composition of the present invention significantly decreases the expression of nuclear transcription factors (C/EBPα and PPARγ2) which play a key role in adipogenesis in the visceral adipose tissue, or target genes thereof, to thereby decrease abdominal fat. The composition significantly decreases the expression of cytokine (TNF-α or IL-6) which causes inflammatory activation, to thereby improve chronic inflammatory activation induced by obesity in visceral adipose tissue. The composition increases the expression of the UCP (UCP1 or UCP3) genes which adjust thermogenesis in the body, to thereby improve the inhibition of thermogenesis induced by obesity in visceral adipose tissue.
Neuronavigated rTMS will be delivered using neuro-navigation based on participants' own MRI images to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
The present invention provides a method of human gene therapy using AAV vectors with essentially wildtype phenotype. Genes of 900 bases or less can be inserted into wildtype AAV and still allow the resulting vector to have a largely wildtype phenotype. For example, several antisense genes could be inserted and still allow packaging. Such wildtype vectors have several advantages. First, high titers of such vectors is easy to accomplish. Second, the vectors, since they include the Rep78 gene, integrate specifically into human chromosome 19. Third, such vectors, being wildtype, spread after their initial introduction. Another method for use of large wildtype AAV genomes is as complementors for fully defective AAV vectors. Such complementors can be delivered by virus infection and, be introduced easily into 100% of the cells used to produce virus. Viral infection is superior to synthetic techniques for introducing DNA into tissue culture producer cells. When large essentially wildtype AAV complementor virus are used in conjunction with AAV vector virus allowing for the introduction of both vectors into all cells, high titers of recombinant AAV virus is achieved.
IMPORTANCE: Allergic rhinitis affects an estimated 15% of the US population (approximately 50 million individuals) and is associated with the presence of asthma, eczema, chronic or recurrent sinusitis, cough, and both tension and migraine headaches.
OBSERVATIONS: Allergic rhinitis occurs when disruption of the epithelial barrier allows allergens to penetrate the mucosal epithelium of nasal passages, inducing a T-helper type 2 inflammatory response and production of allergen-specific IgE. Allergic rhinitis typically presents with symptoms of nasal congestion, rhinorrhea, postnasal drainage, sneezing, and itching of the eyes, nose, and throat. In an international study, the most common symptoms of allergic rhinitis were rhinorrhea (90.38%) and nasal congestion (94.23%). Patients with nonallergic rhinitis present primarily with nasal congestion and postnasal drainage frequently associated with sinus pressure, ear plugging, muffled sounds and pain, and eustachian tube dysfunction that is less responsive to nasal corticosteroids. Patients with seasonal allergic rhinitis typically have physical examination findings of edematous and pale turbinates. Patients with perennial allergic rhinitis typically have erythematous and inflamed turbinates with serous secretions that appear similar to other forms of chronic rhinitis at physical examination. Patients with nonallergic rhinitis have negative test results for specific IgE aeroallergens. Intermittent allergic rhinitis is defined as symptoms occurring less than 4 consecutive days/week or less than 4 consecutive weeks/year. Persistent allergic rhinitis is defined as symptoms occurring more often than 4 consecutive days/week and for more than 4 consecutive weeks/year. Patients with allergic rhinitis should avoid inciting allergens. In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamine (eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas patients with persistent moderate to severe allergic rhinitis should be treated initially with an intranasal corticosteroid (eg, fluticasone, triamcinolone, budesonide, mometasone) either alone or in combination with an intranasal antihistamine. In contrast, first-line therapy for patients with nonallergic rhinitis consists of an intranasal antihistamine as monotherapy or in combination with an intranasal corticosteroid.
CONCLUSIONS AND RELEVANCE: Allergic rhinitis is associated with symptoms of nasal congestion, sneezing, and itching of the eyes, nose, and throat. Patients with allergic rhinitis should be instructed to avoid inciting allergens. Therapies include second-generation H1 antihistamines (eg, cetirizine, fexofenadine, desloratadine, loratadine), intranasal antihistamines (eg, azelastine, olopatadine), and intranasal corticosteroids (eg, fluticasone, triamcinolone, budesonide, mometasone) and should be selected based on the severity and frequency of symptoms and patient preference.
The invention provides a new coronary lesion segmentation method based on multi-scale feature fusion. Based on a U-Net semantic segmentation network with an excellent segmentation effect in the image segmentation field, a plurality of combination strategies of a void space convolution pooling pyramid and a CBAM attention mechanism are added for improvement. And (3) sending the image features into a void space convolution pooling pyramid and a CBAM attention mechanism to realize various combination strategies at the same time of downsampling each time. And capturing multi-scale information through the global pooling layer and the sampling rate of the set cavity convolution. The CBAM attention mechanism is based on a hollow space convolution pooling pyramid, and channel attention and space attention are used in series. Modeling is carried out on the spatial dimension, so that the model strengthens important channel characteristics and ignores channel characteristics with smaller response. And during training, the mode of fusing the Dice Loss and the BCE Loss is used for tuning, so that effective information is selectively emphasized, and ineffective information is inhibited. The multi-scale focus semantic information fusion is realized, the deep features of the image are better extracted, and the segmentation effect is better. Experimental data show that the improved network has a better segmentation effect. Is stable and has a certain reference value compared with the prior structure.